Cubist Systematic Strategies, LLC Revance Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 230,609 shares of RVNC stock, worth $592,665. This represents 0.0% of its overall portfolio holdings.

Number of Shares

230,609

Holding current value

$592,665

% of portfolio

0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $592,665 - $592,665	230,609 New	230,609 $592,000
Q1 2024 May 15, 2024	SELL	$4.65 - $9.31 $1.26 Million - $2.51 Million	-269,926 Reduced 88.37%	35,521 $174,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $495,209 - $954,620	85,234 Added 38.71%	305,447 $2.68 Million
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $465,613 - $1.02 Million	-40,594 Reduced 15.56%	220,213 $2.53 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $2.15 Million - $3.28 Million	87,121 Added 50.16%	260,807 $6.6 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $2 Million - $3.85 Million	-109,141 Reduced 38.59%	173,686 $5.59 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $3.23 Million - $5.4 Million	176,199 Added 165.25%	282,827 $5.22 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $1.99 Million - $3.95 Million	-138,584 Reduced 56.52%	106,628 $2.88 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $2.55 Million - $4.52 Million	221,707 Added 943.23%	245,212 $3.39 Million
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $395,532 - $649,940	-32,001 Reduced 57.65%	23,505 $458,000
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $443,675 - $992,394	35,608 Added 178.95%	55,506 $906,000
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $381,544 - $491,508	-14,800 Reduced 42.65%	19,898 $554,000
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $723,814 - $859,934	27,008 Added 351.21%	34,698 $1.03 Million
Q1 2021 May 17, 2021	BUY	$24.03 - $29.97 $184,790 - $230,469	7,690 New	7,690 $215,000
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $797,157 - $965,033	-34,052 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $791,027 - $1.17 Million	34,052 New	34,052 $856,000
Q2 2020 Aug 14, 2020	SELL	$12.6 - $26.55 $1.37 Million - $2.88 Million	-108,435 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$12.46 - $27.81 $776,881 - $1.73 Million	62,350 Added 135.29%	108,435 $1.61 Million
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $537,351 - $928,612	46,085 New	46,085 $748,000
Q3 2019 Nov 14, 2019	SELL	$10.22 - $14.5 $367,736 - $521,739	-35,982 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $5,025 - $7,295	471 Added 1.33%	35,982 $467,000
Q1 2019 May 15, 2019	BUY	$15.4 - $20.39 $546,869 - $724,069	35,511 New	35,511 $560,000
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $207,122 - $264,729	-8,795 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $72,852 - $88,510	2,654 Added 43.22%	8,795 $241,000
Q1 2018 May 15, 2018	BUY	$29.15 - $37.4 $179,010 - $229,673	6,141 New	6,141 $189,000

Others Institutions Holding RVNC

# of Institutions

230

Shares Held

81.5M

Call Options Held

617K

Put Options Held

870K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Revance Therapeutics, Inc. Transaction History